Back to resultsAn Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
Primary Purpose
Glaucoma, Ocular Hypertension
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
travoprost, latanoprost, or bimatoprost
Additional ocular hypotensive medication
Sponsored by
About this trial
This is an interventional diagnostic trial for Glaucoma focused on measuring Glaucoma, Compliance
Eligibility Criteria
Inclusion Criteria: Currently using one or two topical ocular hypotensive medications Exclusion Criteria: Hypersensitivity to any component of medication
Sites / Locations
Outcomes
Primary Outcome Measures
Compliance.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00329095
Brief Title
An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
Official Title
An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures
Study Type
Interventional
2. Study Status
Record Verification Date
May 2006
Overall Recruitment Status
Completed
Study Start Date
December 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
April 2006 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Robin, Alan L., M.D.
4. Oversight
5. Study Description
Brief Summary
This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.
Detailed Description
This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma, Ocular Hypertension
Keywords
Glaucoma, Compliance
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
travoprost, latanoprost, or bimatoprost
Intervention Type
Drug
Intervention Name(s)
Additional ocular hypotensive medication
Primary Outcome Measure Information:
Title
Compliance.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Currently using one or two topical ocular hypotensive medications
Exclusion Criteria:
Hypersensitivity to any component of medication
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alan L. Robin, MD
Organizational Affiliation
Alan L. Robin, M.D.
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
17686450
Citation
Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007 Oct;144(4):533-40. doi: 10.1016/j.ajo.2007.06.012. Epub 2007 Aug 8.
Results Reference
derived
Learn more about this trial
An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
We'll reach out to this number within 24 hrs